Filing Flows › X4 Pharmaceuticals (XFOR) › Q3 2026
X4 Pharmaceuticals (XFOR) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
X4 Pharmaceuticals (XFOR) reported revenue of $2.8M for the third quarter 2026 (Q3 2026), +75% from a year earlier and +17% from the quarter before. Operating margin was -714.0%, net loss $20.2M (721.4% of revenue).
X4 Pharmaceuticals, Q3 2026: revenue $2.8M (+75% year over year), operating margin -714.0%, net loss $20.2M, operating cash flow −$20.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | +17% | +75% |
| Operating profit | −$20.0M | — | — |
| Net earnings | −$20.2M | — | — |
| Operating cash flow | −$20.2M | — | — |
What changed
Revenue was $2.8M in Q3 2026, up 75% year over year and up 17% from the previous quarter. Product revenue, net was the largest line at 99% of revenue. Product revenue, net added $1.2M year over year (up 77%), 101% of the total change. License and other revenue declined 47%.
Operating costs exceeded revenue by $20.0M, an operating margin of -714.0%. Total costs fell 22% while revenue rose 75%. The quarter ended with a net loss of $20.2M, wider than the previous quarter's $16.2M loss.
Operating cash flow was −$20.2M. Non-cash charges added back $331K of depreciation and amortization and $3.5M of share-based compensation. Working capital and other items used $3.8M.
Questions
What was X4 Pharmaceuticals' revenue in the third quarter 2026?
X4 Pharmaceuticals (XFOR) reported revenue of $2.8M for the third quarter 2026 (Q3 2026), +75% from a year earlier and +17% from the quarter before.
Was X4 Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $20.0M (-714.0% of revenue) and net loss $20.2M.
Source: X4 Pharmaceuticals 10-Q on SEC EDGAR.